The Optos California, an ultra-widefield retinal ... The system was designed "to identify pathology in the retinal periphery efficiently and correlate it with disease progression and management ...

Please provide your email address to receive an email when new articles are posted on . Atsena Therapeutics completed patient dosing in part A of the phase 1/2 LIGHTHOUSE clinical trial ...

Retinal imaging firm Optos is planning to expand its product ... clinical evidence that confirms the critical importance of the periphery in retinal diagnostics." Mr Davis said the firm's ...

"By integrating Optos' widefield retinal imaging technology with a widefield OCT capability, we aim to bring a new depth of imaging to both the central pole and the periphery of the retina for the ...

The company also noted that "both eye and non-eye diseases often first exhibit in the periphery of the retina". Under its business model, Optos turned over $100.8m for the year to the end of ...

Optos’s retinal imagery devices can do what others cannot — it is the only system capable of mapping as much as 82% of the retina and its all-important periphery, which is so hard to capture.